<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Dog Parvo Symptoms &#187; Treatment</title>
	<atom:link href="http://dogparvosymptoms.org/category/treatment/feed/" rel="self" type="application/rss+xml" />
	<link>http://dogparvosymptoms.org</link>
	<description>Dog Parvo And Dog Health Information</description>
	<lastBuildDate>Wed, 11 Nov 2009 12:38:48 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Oral malignant melanomas and benign lesions</title>
		<link>http://dogparvosymptoms.org/oral-malignant-melanomas-and-benign-lesions/</link>
		<comments>http://dogparvosymptoms.org/oral-malignant-melanomas-and-benign-lesions/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:38:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=152</guid>
		<description><![CDATA[Oral malignant melanomas:

Oral malignant melanomas really belong in a separate category. This type  of tumor tends to respond in a similar way to radiation therapy as do late  responding tissues. In such cases, when typical standard curative protocols are  used to spare the late responding tissues, the tumor cells are also spared. [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Oral malignant melanomas:<br />
</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Oral malignant melanomas really belong in a separate category. This type  of tumor tends to respond in a similar way to radiation therapy as do late  responding tissues. In such cases, when typical standard curative protocols are  used to spare the late responding tissues, the tumor cells are also spared. For  this reason, a better success rate in tumor control has been achieved with the  use of larger and fewer fractions. In human medicine research, an effort has  been made to try to differentiate melanoma tumors that respond better to large  fractions from those that would respond better to smaller fractions. To date,  this remains unresolved and, for the most part, a coarse fractionation protocol  is chosen. In veterinary medicine, most protocols consist of fractions between 6  to 10 Gy. Malignant melanomas are usually locally invasive and fairly quick to  metastasize. Approximately 75% of cases will die of metastatic disease despite  good local control. For this reason, chemotherapy for systemic disease should be  considered. Unfortunately, an effective agent for this cancer has yet to be  identified. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Benign lesions:<br />
</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">It  should be realized that although radiotherapy is mostly used for the control of  malignant cancer, certain benign lesions (for example: infiltrative lipomas,  Granulomatous meningoencephalomyelitis (GME), and chronic lick granulomas  non-responsive to medical treatment?) have been successfully treated as well.  Like always, the risks and benefits must all be taken into consideration for  each </span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">individual case.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">T. Control-1  and CompL-1 show the probability of Tumor control and Normal Late Tissue  Complications for a protocol of lower fractionation while T.Control-2 and  CompL-2 show the probability of Tumor control and Normal Late Tissue  Complications for a highly fractionated protocol.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">As a general  rule, a prescribed treatment protocol should have no more than a 10% probability  of inducing serious late complications for most tissues, and no more than a 5%  probability of late complications for nervous tissue. Due to improved time-dose  fractionation, computer treatment planning, and the use of megavoltage therapy,  a serious complication rate of less than 5% exists in most veterinary radiation  therapy today.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/oral-malignant-melanomas-and-benign-lesions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Palliative Radiation Therapy</title>
		<link>http://dogparvosymptoms.org/palliative-radiation-therapy/</link>
		<comments>http://dogparvosymptoms.org/palliative-radiation-therapy/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:35:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=150</guid>
		<description><![CDATA[Despite advanced technologies and extensive research, many cancers are still  left without a definite cure. When cancer has a vast systemic dissemination,  palliation becomes the main goal of therapy. Palliative radiotherapy treats  local discomfort caused by either the primary tumor site or by enlarged  metastatic lymph nodes. Approximately 50% of human [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Despite advanced technologies and extensive research, many cancers are still  left without a definite cure. When cancer has a vast systemic dissemination,  palliation becomes the main goal of therapy. Palliative radiotherapy treats  local discomfort caused by either the primary tumor site or by enlarged  metastatic lymph nodes. Approximately 50% of human cancer patients with terminal  disease undergo a palliative radiation treatment. In veterinary medicine, the  most common example of palliative radiotherapy is for treatment of painful bone  cancer (either a primary bone cancer like osteosarcoma, or metastatic bone  cancer). Since palliation is the main goal of the treatment, the protocol should  be designed so acute effects are minimal to non-existent (so we actually  palliate instead of inducing additional discomfort). This is achieved by  applying coarser fractionation – which also increases the probable occurrence of  late complications if the patient survives longer than expected. Thus, the  standard curative fractionation protocol should be altered within reason since  some patients will survive past 6 months, particularly when adjuvant  chemotherapy is used or<br />
when the cancer metastasizes more slowly than  anticipated.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Various protocols have been  applied for palliation in both veterinary and human medicine. The fraction size  administered will depend on the site being irradiated and the individual case.  The sensitivity of the tissues included in the field must still be taken into  consideration, just as they are with curative protocols. For example, a  treatment involving brain tissue would be approached slightly differently than  one involving a distal extremity. The degree of coarse fractionation and the  optimal total dose for palliative protocols is still an area of debate in both  human and veterinary therapy. Generally, however, three fractions of 8 to 10 Gy  is administered. Approximately 70% of osteosarcoma patients show a positive  response to palliative radiotherapy and most show clinical pain relief within 2  to 3 weeks of the start of treatment. Response can occur anywhere between a few  hours after the initial dose to 6 weeks after the first course of treatment.  When a second course is required for pain recurrence, 80 % of patients who  responded well the first time will again<br />
have a positive response.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Palliative therapy of soft  tissue tumors may be beneficial when a mass is impairing function or causing  discomfort due to tissue compression. This would include masses causing  urethral, tracheal or laryngeal/pharyngeal, esophageal colorectal, lymphatic,  vascular (ex: Vena Cava), or other types of obstructions or masses inducing  painful tissue compression such as pressure on the spinal cord, nerve root,  brain tissue or orbital tissue.</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/palliative-radiation-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Periorbital, Auricular, Thyroid and Other Tumors</title>
		<link>http://dogparvosymptoms.org/periorbital-auricular-thyroid-other-tumors/</link>
		<comments>http://dogparvosymptoms.org/periorbital-auricular-thyroid-other-tumors/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:34:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=148</guid>
		<description><![CDATA[Periorbital  and facial tumors:
Many types of  tumors may occur in this area. Examples may include Lymphoma, Osteosarcoma,  Mast cell tumor, Reticulum cell sarcoma, Fibrosarcoma, optic nerve Meningioma,  Neurofribrosarcoma, Glial,Carcinomas, Undifferentiatedtumors, and  others
Periorbital  tumors may originate from either the surrounding soft tissues, or bone, or may  result from extension [...]]]></description>
			<content:encoded><![CDATA[<p><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Periorbital  and facial tumors:</strong></span></p>
<p><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Many types of  tumors may occur in this area. Examples may include <strong>Lymphoma, Osteosarcoma,  Mast cell tumor, Reticulum cell sarcoma, Fibrosarcoma, optic nerve Meningioma,  Neurofribrosarcoma, Glial,Carcinomas</strong>, <strong>Undifferentiatedtumors</strong>, and  others</span></p>
<p><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Periorbital  tumors may originate from either the surrounding soft tissues, or bone, or may  result from extension of other primary tumors originating in the nasal cavity,  maxilla or optic nerve. Many of these tumors cannot be completely resected  surgically with good margins because of location and surrounding critical  tissues. Response to radiation greatly depends on the type and grade of tumor.  Many periorbital tumors are successfully treated with radiation therapy, with or  without adjuvant therapy.</span></p>
<p><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Auricular  and periauricular tumors:</strong></span></p>
<p><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Theoretically,  any cutaneous or soft tissue tumors can occur in the periauricular area. It is  not uncommon to find <strong>Mast cell tumors, Fibrosarcomas and other Soft tissue  sarcomas</strong>. As with treating these tumors in other areas of the body,  radiation therapy has been successful, although the success rate depends on the  grade and type of tumor.</span></p>
<p><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Ceruminous  gland adenocarcinoma</strong> (CGA) is the most common tumor of the ear canal found  in both dogs and cats. In one study, aggressive surgery (ablation of the ear  canal and bulla osteotomy) resulted to a median disease-free interval of 42  months. Another study using radiation alone, or in combination with surgery,  resulted in a tumor-free survival time of 39 months. In cats, when the tumor  invades outside the ear, surgery alone is unlikely to result to a long-term  remission and radiation is usually required as an adjuvant treatment for better  tumor control.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Squamous cell carcinoma </strong>of the ear canal and bulla tend to be more invasive, have a higher  metastatic potential, and often compromise the adjacent brain tissue. Thus, the  prognosis is significantly poorer than CGA, and these tumors should be  thoroughly staged before the type of treatment is considered.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Pharyngeal,  laryngeal, thyroid and other:</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Common  malignant tumors occurring in these areas include: Osteosarcoma, Chondrasarcoma,  Undifferentiated carcinoma, Fibrosarcoma, Mast cell, Adenocarcinoma, Squamous  cell carcinoma, Plasmacytoma and Lymphoma. </strong>Limited data is available on  malignant tumors in these regions since few have been reported, but most do tend  to be very invasive with significant metastatic behavior. Depending on the tumor  type and its expected radiosensitivity (based on treatments at other sites),  radiation may help control the tumor while preserving laryngeal function.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Radiation is  expected to offer good control of <strong>Lymphoma</strong> and <strong>Plasmacytoma</strong> of  laryngeal and/or tracheal involvement.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Oncocytoma </strong>(also  called rhabdomyoma) is a rare benign tumor involving the larynx and usually  occurs in the younger mature dog. These tumors are usually successfully resected  surgically, have a good prognosis, and are potentially curable. No data is  presently available regarding radiation therapy of non-resectable  oncocytomas.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Malignant thyroid  carcinomas </strong>are unfortunately not as responsive to radiation therapy as are  benign adenomas. I<sup>131</sup>treatment for malignant tumors has been  attempted but does not result to the same satisfying success rate achieved in  the hyperthyroid cats with benign tumors. Malignant thyroid tumors are best  approached with a combination of surgery followed by external beam radiation or  I<sup>131</sup>radiation treatment and chemotherapy. Although radiation therapy  has been attempted on this type of tumor, data is limited due to the small  number of reports.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/periorbital-auricular-thyroid-other-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiotherapy for Intrathoracic and Abdominal Tumors</title>
		<link>http://dogparvosymptoms.org/radiotherapy-for-intrathoracic-and-abdominal-tumors/</link>
		<comments>http://dogparvosymptoms.org/radiotherapy-for-intrathoracic-and-abdominal-tumors/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:30:13 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=146</guid>
		<description><![CDATA[Intrathoracic  tumors:
Long-term tumor control has  been obtained with surgical resection of Thymomas. However, about 50% are  not resectable. Although limited data is available, tumor remission has been  reported following radiation therapy alone or combined with surgery (either  before or after). When both modalities are used in combination, it is suggested [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Intrathoracic  tumors:</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Long-term tumor control has  been obtained with surgical resection of <strong>Thymomas</strong>. However, about 50% are  not resectable. Although limited data is available, tumor remission has been  reported following radiation therapy alone or combined with surgery (either  before or after). When both modalities are used in combination, it is suggested  that radiation be performed before surgery to avoid possibly increasing the  amount of hypoxic cells created by surgery-induced tumor vasculature  damage.</span></p>
<ul>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Mediastinal lymphoma</strong> refractory to chemotherapy has been treated with radiation therapy with variable  results. Many go on to developing systemic signs shortly after treatment.  However, while limited data exists, some cases of primary mediastinal lymphoma  have responded well to radiation therapy on initial diagnosis with adjuvant  chemotherapy for potential systemic disease. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Other thoracic tumors such  as <strong>Chemodectomas</strong>, imcompletely resected <strong>Right atrial  hemangiosarcomas,</strong> incompletely resected primary <strong>Lung tumors</strong>, and  <strong>other heart base or mediastinal tumors</strong> have been approached with  combination of surgery and radiation +/- chemotherapy. Data on treating these  tumors is very limited and the decision to treat with radiation alone, or as  part of a combination, should be based on a case-by-case basis using the basic  principles of radiation oncology.</span></p>
</ul>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Abdominal and Perianal  tumors:</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Very little data is  available on radiation therapy of bladder tumors. <strong>Transitional cell  carcinomasof the bladder</strong> have been successfully treated with a combination  of radiation and chemotherapy (+/- surgery) with a median survival time of  almost 1 year.</span></p>
<ul>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"> </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">As with bladder tumors, data  on radiation therapy of <strong>Anal sac adenocarcinomas </strong>is scarce. They are,  however, commonly treated with a combination of radiation and chemotherapy with  a median survival time of over1 year. These tumors have a relatively high  metastatic potential, with approximately 50% of patients first presenting with  evidence of iliac/sublumbar lymphatic metastasis. Therefore, the sublumbar  region is included in the radiation treatment field. Chemotherapy is also  recommended as an adjuvant to treat metastatic disease even if not clinically  evident.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Other <strong>Perianal tumors</strong> such as <strong>Perianal gland adenomas and adenocarcinomas</strong>, most often occurring  in males, are best treated with surgical resection (aggressive when malignant).  When good margins cannot be obtained on adenocarcinomas, radiation therapy is  recommended. Regional lymph node metastasis is common. Some 50% are successfully  surgically resected, but radiation therapy in combination with chemotherapy  should result in a prolonged remission interval in non-resectable  cases.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Prostatic tumors</strong> and  <strong>Testicular tumors</strong> of retained testicles or lymphatic metastasis of either  type can be treated with radiation therapy. Primary testicular tumors and  testicular tumor lymphatic metastasis has been successfully treated with  radiation therapy. The prognosis greatly depends on the extent of the local  invasion and the degree of metastasis at presentation. Prostatic tumors, on the  other hand, usually have a poor prognosis no matter what treatment modality is  used. Approximately 70-80% already have advanced skeletal metastatic disease of  the lumbar spine, sacrum and/or pelvis on presentation, or extensive local  invasion of the urethra, bladder or colon. Radiation therapy has been attempted  on occasion, however data is limited. For the most part, treatment of these  cases are usually geared toward a palliative intent.</span></p>
</ul>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiotherapy-for-intrathoracic-and-abdominal-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiotherapy for Bone, Joints and Spinal Tumors</title>
		<link>http://dogparvosymptoms.org/radiotherapy-for-bone-joints-and-spinal-tumors/</link>
		<comments>http://dogparvosymptoms.org/radiotherapy-for-bone-joints-and-spinal-tumors/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:27:13 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=143</guid>
		<description><![CDATA[Bone, joints and spinal  tumors:
Osteosarcoma (OSA) is  by far the most common primary bone tumor. Other primary bone tumors, such as  Chondroma/chondrosarcoma, Hemangiosarcoma, Fibrosarcoma, and Multilobular  osteochondrosarcoma (MLO, Chondroma rodens) may occur. A definitive  diagnosis is not possible without a bone biopsy &#8211; but performing a biopsy risks  causing [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Bone, joints and spinal  tumors:</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Osteosarcoma (OSA)</strong> is  by far the most common primary bone tumor. Other primary bone tumors, such as  <strong>Chondroma/chondrosarcoma, Hemangiosarcoma, Fibrosarcoma, and Multilobular  osteochondrosarcoma (MLO, Chondroma rodens)</strong> may occur. A definitive  diagnosis is not possible without a bone biopsy &#8211; but performing a biopsy risks  causing a pathologic fracture at the biopsy site (because of the bone is so  friable with tumor destruction). Thus, a final diagnosis is not always  available. OSA tumors have a very high metastatic potential, and most patients  already have microscopic pulmonary metastasis on presentation. Therefore, while  radiation therapy is not usually curative and does not increase survival time,  it is a very effective <strong>palliative treatment </strong>when surgery or amputation  has been declined. Approximately 70% of these patients have a positive response  to palliative radiotherapy. (Refer to handout subtitle <span style="text-decoration: underline;">Palliative radiation  therapy</span> for more detailed information.)</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>MLO</strong> generally occur  on canine skulls and will often recur if not fully resected. Approximately 50%  will metastasize (usually within the first year after treatment) and the median  survival time is about 21 months. Although both chemo and radiation therapy have  been administered to these patients, the exact role and efficiency of these  adjuvant modalities are not yet well defined.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Feline osteosarcomas </strong>have a lower metastatic potential and, thus, a significantly better  prognosis, compared to the same tumors in dogs. Median survival time in cats  with osteosarcoma, with no evidence of metastatic disease, treated with  amputation alone, is 2 years. Their better prognosis may make radiation therapy  (not as a palliative approach) more reasonable in cases where complete surgical  resection is not an option.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Multiple myeloma</strong>,  <strong>Lymphoma of the bone marrow </strong>and <strong>bone metastases </strong>can be painful,  and may be successfully managed with palliative treatment. As with primary bone  tumors, radiation is not used to increase survival time but to control pain and  offer local comfort in sites non-responsive to conservative medical treatment. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">The prognosis of <strong>Synovial  cell carcinoma </strong>is greatly dependent on the grade and stage of the tumor.  Approximately 22 % have evident metastatic disease on presentation, and require  chemotherapy. Grade III tumors (most malignant) are best treated with amputation  +/- chemotherapy. When amputation is declined, aggressive local surgical  resection followed by radiation therapy (+/- chemotherapy) is the most  appropriate treatment. One reported isolated case, treated with surgery and  radiation, showed no evidence of neoplastic disease 2 years after treatment  (deceased from unrelated cause).</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"> </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Spinal bone tumors  (primary or secondary)</strong> have been treated with palliative radiotherapy &#8211;  often on an emergency basis when they cause significant neurological signs and  paralysis. Just as bone tumors of the limbs show a pain relief response to  radiation, neurological improvement and pain relief has been observed as soon as  a few hours to a few weeks following the initial radiation treatment of spinal  bone tumors. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Normal lymphocytes are  extremely radiosensitive. However, resistance to chemo and radiation therapy has  also been noted. Little is reported regarding the response of <strong>Spinal  lymphosarcoma</strong> to radiation. In one study one three cases of feline  lymphosarcoma treated with chemotherapy and radiation therapy, two cats had a  positive response to radiotherapy while one continued to deteriorate. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Tumors of the spinal  nervous tissue</strong> – like brain tumors &#8211; generally respond to radiation in a  similar fashion. When feasible, surgery combined with radiation should offer the  best long-term prognosis. If both are combined as a treatment the total  radiation dose is slightly decreased to reduce potential late complications.  Therefore, these options need to be thoroughly discussed if initiating radiation  before surgery. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiotherapy-for-bone-joints-and-spinal-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiotherapy For Oral Tumors</title>
		<link>http://dogparvosymptoms.org/radiotherapy-for-oral-tumors/</link>
		<comments>http://dogparvosymptoms.org/radiotherapy-for-oral-tumors/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:24:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=140</guid>
		<description><![CDATA[Oral tumors: 
Maxillary, mandibular, lingual,  tonsilar and salivary  glands.
Aggressive surgical  excision, whenever feasible, usually yields the highest survival times and tumor  control. Adequate surgical margins are often difficult to achieve in the oral  cavity, so adjuvant radiation therapy is required for residual disease.  Radiation therapy is effective for incompletely [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Oral tumors: </strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Maxillary, mandibular, lingual,  tonsilar and salivary  glands.</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Aggressive surgical  excision, whenever feasible, usually yields the highest survival times and tumor  control. Adequate surgical margins are often difficult to achieve in the oral  cavity, so adjuvant radiation therapy is required for residual disease.  Radiation therapy is effective for incompletely resected or for non-resectable  oral tumors (either due to critical tissue involvement or due to declination of  the procedure by the owners).</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">While <strong>Acanthomatous  epulides</strong> do not metastasize, they are often locally aggressive and  destructive; requiring an aggressive response. They are very responsive to  radiation therapy either as a sole modality or as a complement to surgery.  Median survival times of over 3 years have been reported (with an 85% 1 year  survival rate).</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Low-grade fibrosarcoma,  nodular fascitis, invasive fibroma and granulation tissue</strong>. Be particularly  cautious if one of the above is listed as originating from an oral or facial  mass. There is a form of fibrosarcoma that behaves very aggressively while  appearing very benign histologically. If this clinical behavior is noted,  another histopathological opinion is recommended. An aggressive approach to  these tumors is mandatory because they progress very quickly and are extremely  locally invasive. Ideally, these are best approached with a combination of  radiation followed by surgery.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Canine Squamous cell  carcinomaSSC</strong> is best treated with a combination of radiation therapy,  surgery and chemotherapy. A 1-2 year survival time has been achieved with  radiation and surgery, while radiation alone had a median survival of  approximately 16 months. Prognosis and tumor response depends on location (the  most rostral lesions have a higher success rate than caudal lesions), which is  also true for Lingual SCC. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Good tumor control is not as  successfully achieved in <strong>Feline SCC</strong> as in canine SSC. The most aggressive  approach combining radiation, surgery and chemotherapy yields the best results.  Radiation alone, radiation plus chemotherapy, and surgery plus radiation do  produce positive results but survival times are not as long as achieved in  treating canine SCC.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Malignant melanomas</strong> do respond to radiation, but tend to respond better to fewer but larger doses.  While local control is usually gained with radiation therapy, many of these  cases metastasize and are best treated with radiation and some form of  chemotherapy and/or immunotherapy. Unfortunately, an agent to systemically  control this particular cancer has yet to be identified. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Normal lymphocytic cells are  generally very radiosensitive. Radiation therapy is very effective in treating  <strong>Focal lymphosarcoma</strong> and particularly effective as an emergency treatment  of obstructive oral lymphoma of the tongue and pharyngeal region.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Mycosis fungoides</strong> is  a cutaneous neoplastic process involving helper T-cells. A variation of mycosis  fungoides limited to the oral cavity and mucocutaneous margins has been  successfully treated with radiation therapy alone. In widespread cases involving  both the oral cavity and multiple cutaneous sites, radiation therapy has  successfully treated the oral cavity and certain painful cutaneous lesions that  are non-responsive to chemotherapy.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Local recurrence of  <strong>Salivary tumors</strong> commonly results within 6 months following surgery alone,  suggesting the need for adjuvant therapy. Limited data is available regarding  radiation therapy, but a report on three cases treated with radiation and  surgery obtained tumor control durations of 12, 25 and 40 months. Chemotherapy  should also be considered for metastatic disease.</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiotherapy-for-oral-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiotherapy For Brain and Nasal Tumors</title>
		<link>http://dogparvosymptoms.org/radiotherapy-for-brain-and-nasal-tumors/</link>
		<comments>http://dogparvosymptoms.org/radiotherapy-for-brain-and-nasal-tumors/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:18:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=122</guid>
		<description><![CDATA[Brain  tumors:
(Meningiomas, pituitary  macrotumors, other brain tumors and GME)
Meningiomas and pituitary  tumors are generally more radioresponsive than other types of brain tumors. 
The treatment of choice for  Feline meningioma is surgery when feasible (depending on location).  Radiation therapy is effective when surgical resection is not possible. 
The treatment of choice [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Brain  tumors:</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>(Meningiomas, pituitary  macrotumors, other brain tumors and GME)</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Meningiomas and pituitary  tumors are generally more radioresponsive than other types of brain tumors. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">The treatment of choice for  <strong>Feline meningioma</strong> is surgery when feasible (depending on location).  Radiation therapy is effective when surgical resection is not possible. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">The treatment of choice for  <strong>Canine meningioma</strong> is either a combination of surgery and radiation  therapy, or radiotherapy alone.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Radiation therapy is an  effective treatment of <strong>Pituitary macrotumors</strong> and has become the safest  and most common treatment. The response and survival time is usually dependent  on the severity of neurological signs. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">While not a neoplastic  process, some <strong>GME (granulomatous meningoencephalo-myelitis) cases </strong>unresponsive to cortico-steroids have responded well to  irradiation.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Irradiation of <strong>other  Intracranial tumors</strong> (most without a definite diagnosis) has significantly  increased survival time compared to strictly medically-treated cases. Response  to treatment is usually dependent on the severity of neurological signs (the  more neurological impairment, the worse the prognosis).</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Nasal tumors: </strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Nasal, paranasal sinuses,  and nasal plenum</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">For the most part, studies  on <strong>tumors of thenasal cavity and paranasal sinuses</strong> in canines have been  grouped together. Aggressive surgery followed by orthovoltage therapy has  produced the best survival times (median of approximately 23 months). When using  megavoltage therapy, prior surgery decreases the success rate (mean and median  survival of approximately 21 and 13 months respectively).</span></p>
<ul>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">In a recent study,  megavoltage therapy combined with (OPLA)-cisplatin (not yet available on the  market) has increased survival times to a median of some 24 months.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">In the cat, similar survival  times have been achieved as found in the dog.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Little data is available  on<strong> Solitary nasal lymphoma</strong> in dogs, due to the rarity of cases. Nasal  lymphoma in cats is well documented and has been successfully treated with  radiation therapy, with and without chemotherapy, resulting to a median survival  time of approximately 2 years. A similar survival time was achieved in an  isolated canine case treated with megavoltage radiation combined with  (OPLA)-cisplatin.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Squamous cell carcinoma  (SCC) of the nasal plenum</strong> in felines is most successfully treated with  surgery (the use of radiation therapy depends on the tumor margins). Cases  treated with radiation therapy alone have also responded well. The prognosis and  disease-free interval depends largely on the clinical stage at the start of  treatment.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Unfortunately, <strong>SCC of the  nasal plenum</strong> in canines is more resistant to radiation therapy than SCC of  the nasal cavity. Ultimately these tumors are best approached very aggressively  with a combination of radiation, surgery and chemotherapy. They may be treated  with aggressive surgery (+/- radiation depending on the margins) if found when  still relatively superficial. Radiation alone does not appear promising.<br />
</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></ul>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiotherapy-for-brain-and-nasal-tumors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiotherapy For Tumor Control</title>
		<link>http://dogparvosymptoms.org/radiotherapy-for-tumor-control/</link>
		<comments>http://dogparvosymptoms.org/radiotherapy-for-tumor-control/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:15:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=120</guid>
		<description><![CDATA[Radiotherapy is a local cancer treatment modality and not meant to treat  systemic disease. As previously mentioned, it is often combined with other  adjuvant cancer treatment modalities, particularly chemotherapy and surgery.  Covering every type of tumor is beyond the scope of this article. Below, is a  table that generally illustrates which [...]]]></description>
			<content:encoded><![CDATA[<p align="justify">Radiotherapy is a local cancer treatment modality and not meant to treat  systemic disease. As previously mentioned, it is often combined with other  adjuvant cancer treatment modalities, particularly chemotherapy and surgery.  Covering every type of tumor is beyond the scope of this article. Below, is a  table that generally illustrates which cases may benefit of radiotherapy, but  each case should be addressed individually since exceptions do exist.</p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Cutaneous and soft tissue  tumors of the trunk and extremities:</strong></span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"> Mycosis  fungoides (see Oral Tumors)</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Cutaneous and soft tissue  tumors of the trunk and extremities </strong>are best approached in most situations  by aggressive surgical resection. However, complete resection is not always  possible because of location. This is particularly difficult when distal limbs  are involved and the amount of normal skin to close the incision becomes  limited. Adjuvant radiation therapy is an effective approach to treat the  residual tumor cells. </span></p>
<ul>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Mast cell tumors </strong>and  <strong>Soft tissue sarcomas</strong> (fibrosarcoma, hemangiopericytoma, malignant fibrous  histiocytoma, Neurofibrosarcoma, myxosarcoma, malignant giant cell tumors etc)  are the most common tumor types treated with a combination of surgery and  radiation. A cooperative study published in the proceedings of Veterinary Cancer  Society reported disease-free intervals of 2 &#8211; 5 years in 88% of patients with  mast cell tumors (MCT) treated with surgery and radiation. A 5-year survival  rate of up to 86% was reported in a study of soft tissue sarcomas (STS) treated  with surgery and radiation at the Animal Medical Center, New York. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">The histological grade of  <strong>MCT </strong>has a great impact on prognosis and should always be obtained before  considering radiation. Because MCT will most commonly metastasize to the local  lymph nodes and abdominal organs, and less commonly to the lungs, an abdominal  ultrasound and radiograph is more critical than a thoracic radiograph for the  staging work up. Local lymph nodes should also be evaluated for staging as they  are often included in the treatment field.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">A grading system has not  been well established for <strong>Soft tissue sarcomas</strong> and is therefore not yet a  routine part of the histopathology report of most laboratories. However, it is  important to recognize that <strong>undifferentiated and fast growing STS </strong>have a  significantly higher metastatic potential, and adjuvant chemotherapy should be  strongly recommended with a significantly more guarded prognosis.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">The <strong>Vaccine-induced  Feline sarcomas</strong> are more aggressive tumors with a higher metastatic  potential than sarcomas unrelated to vaccination, and need to be approached very  aggressively. Presently, the best treatment is radiation therapy administered  FIRST combined with chemotherapy, then followed by aggressive  surgery.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Squamous cell carcinoma  (SCC) </strong>on the trunk and extremities in canines is most commonly treated with  surgical resection and generally has a good prognosis. The histopathologic  characteristics should be thoroughly determined for prognostic purposes and  chemotherapy is recommended for poorly differentiated tumors. For incompletely  resected tumors, radiation therapy of residual disease is  recommended.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Many <strong>other Cutaneous  tumors </strong>(basal cell, plasma cell, etc&#8230;) have been effectively treated with  radiation when incompletely resected. Only limited published data is available  because of their infrequent numbers. This is because many such tumors are  successfully treated with surgery alone. Like all other cases, these should be  approached individually with a thorough diagnostic and staging work up before  determining the most appropriate treatment.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Like most benign tumors,<strong> Infiltrative lipomas </strong>should be approached first with aggressive surgical  resection (many lipomas will recur if the resection is incomplete &#8211; as it may be  when they occur in limbs and infiltrate around critical structures like vessels,  nerves and tendons). Recurring lipomas have been effectively treated with  radiation therapy when complete resection is impossible due to extensive  infiltration.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></ul>
<p align="justify">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiotherapy-for-tumor-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiation Therapy Effect On Cells</title>
		<link>http://dogparvosymptoms.org/radiation-therapy-effect-on-cells/</link>
		<comments>http://dogparvosymptoms.org/radiation-therapy-effect-on-cells/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:08:01 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=116</guid>
		<description><![CDATA[Fractionation affects fast  and slowly proliferating cells in different ways. This is summarized in the  table below:




Table II &#8211; Effects of  radiation dose fractionation on different cell types:




Tumor cells (fast  proliferating)


Normal fast  proliferating (Early responding tissues)


Normal slowly  proliferating (Late responding tissues)




REPAIR
¯tumor  control.


¯side effects and  complications. ­tissue  [...]]]></description>
			<content:encoded><![CDATA[<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Fractionation affects fast  and slowly proliferating cells in different ways. This is summarized in the  table below:</span></p>
<table id="Table2" border="1" cellspacing="1" cellpadding="7" bordercolor="#000000">
<tbody>
<tr>
<td colspan="3">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif; font-size: xx-small;">Table II &#8211; Effects of  radiation dose fractionation on different cell types:</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Tumor cells </strong>(fast  proliferating)</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Normal fast  proliferating</strong> (Early responding tissues)</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>Normal slowly  proliferating</strong> (Late responding tissues)</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>REPAIR</strong></span></p>
<p align="justify"><span style="font-family: Symbol,serif;">¯</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">tumor  control.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Symbol,serif;">¯</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">side effects and  complications. </span><span style="font-family: Symbol,serif;">­</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">tissue  tolerance.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Symbol,serif;">¯¯¯</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">side effects.</span><span style="font-family: Symbol,serif;">­­­</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">tissuetolerance.</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>RE-ASSORTMENT</strong></span></p>
<p align="justify"><span style="font-family: Symbol,serif;">­</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">tumor  control.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Symbol,serif;">­</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">cell death and acute side  effects.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Very little effect since so  slowly proliferating. Requires a huge time interval before effect is  seen.</span></p>
</td>
</tr>
<tr>
<td width="180" valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>RE-POPULATION</strong></span></p>
<p align="justify"><span style="font-family: Symbol,serif;">¯</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">tumor  control.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Symbol,serif;">¯</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">acute side  effects.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Very little effect since so  slowly proliferating. . Requires a huge time interval before effect is  seen.</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><strong>RE-OXYGENATION</strong></span></p>
<p align="justify"><span style="font-family: Symbol,serif;">­</span><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">tumor  control.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Has no  effect.</span></p>
</td>
<td valign="top">
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Has no  effect.</span></p>
</td>
</tr>
</tbody>
</table>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Fractionation – which  requires a higher total dose than single port protocols &#8211; allows for an  increased repair capability of late responding tissues. This, in turn, results  in greater tumor control, and different levels and types of radiation side  effects.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">Radiation side effects are  generally categorized as acute and late. Acute effects are defined as those  occurring during the course of radiation treatment or soon after the completion  of treatment. Late effects only become clinically evident at least six months or  more following the completion of treatment. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">The greater tumor control  created by fractionation creates in a beneficial decrease in late complications.  However, fractionation can also slightly increase the severity of acute side  effects. Despite this, the protocol is justified because early side effects tend  to be reversible (if the damage to the cells is repairable). The damage caused  by late side effects, however, tends to be permanent as it results from slowly  to non-proliferating cell loss. Once these cells have died, the chance of  replacement is virtually non-existent (this is especially important when  irradiating critical tissues like the brain and spinal cord). For this reason,  late effects are of more concern medically than early ones.</span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;">As a general  rule, a prescribed treatment protocol should have no more than a 10% probability  of inducing serious late complications for most tissues, and no more than a 5%  probability of late complications for nervous tissue. Due to improved time-dose  fractionation, computer treatment planning, and the use of megavoltage therapy,  a serious complication rate of less than 5% exists in most veterinary radiation  therapy today. </span></p>
<p align="justify"><span style="font-family: Arial,Helvetica,Univers,Zurich BT,sans-serif;"><br />
</span></p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiation-therapy-effect-on-cells/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Radiation Therapy Time, Dose and Fractionation</title>
		<link>http://dogparvosymptoms.org/radiation-therapy-time-dose-and-fractionation/</link>
		<comments>http://dogparvosymptoms.org/radiation-therapy-time-dose-and-fractionation/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 12:02:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://dogparvosymptoms.org/?p=112</guid>
		<description><![CDATA[Time-dose and fractionation refers to the schedule of the radiation treatments to be administered. The graph above refers to the rate of tumor control and late complications (vertical axis) at a given total administered dose (horizontal axis). The probability of tumor control obviously increases with a higher total dose, but so does the probability of [...]]]></description>
			<content:encoded><![CDATA[<p>Time-dose and fractionation refers to the schedule of the radiation treatments to be administered. The graph above refers to the rate of tumor control and late complications (vertical axis) at a given total administered dose (horizontal axis). The probability of tumor control obviously increases with a higher total dose, but so does the probability of late complications. One way to resolve this problem &#8211; and decrease the rate of late complications &#8211; is to administer the total dose multiple small doses at one time. This is referred to as dose fractionation. Fractionation of the total radiation dose, or fractionation protocols, was first developed for human medicine as far back as 1920. By the 1950s, it was being used in veterinary medicine, but in a coarser fashion because of the need for anesthesia at every treatment. While veterinary fractionation schemes still tend to be slightly coarser than those used in human medicine, they have improved significantly with the advent of safer anesthetic protocols. The basis principle behind fractionation can be found in the 4 R’s in radiation therapy: Repair, Re-assortment, Re-population and Re-oxygenation.</p>
<p>Repair: Radiation’s attack on cells appears to be primarily on the DNA level. Radiation damage to DNA can be described in a grossly simplified manner by limiting the discussion to two patterns: single strand breaks and double strand breaks. One single strand break is usually relatively easy to repair by the cell. Two, separate, single strand breaks are each similarly and individually repaired. However, the closer the two breaks are to one another, the more likely the chromosome or chromatid will break into two separate pieces, becoming a double strand break. A detached piece of chromosome or chromatid can either rejoin the strand in its normal position or in an incorrect one, leading to an aberration. Thus, double strand breaks are less likely to be correctly repaired and may result to lethal damage.</p>
<p>Sublethal damage usually refers to single strand breaks that can easily be repaired &#8211; as long as a second break does not occur too close by before repair is completed. When a small dose of radiation is administered, sublethal damage occurs in multiple areas in a cell. If the cell is not saturated by this damage, and has enough time to repair itself before cell division (or before the next radiation dose), the cell will survive.</p>
<p>Slowly proliferating cells are better able to repair sublethal damage, making them less susceptible to radiation cell death following a fractionated protocol. The time required for completion of the repair is a minimum of 6 hours for most tissues, but tissues from the nervous system usually require additional time. Although all cells will achieve a certain degree of repair during this interval, more slowly proliferating cells will survive than fast proliferating cells. Re-assortment: Cells have varying radio-sensitivities at different phases in their cycle. As a rule, cells tend to be most sensitive during mitosis and the G2 phase of their cycle, and most resistant during the S (synthesis) phase. During the interval between treatments, some cells in the resistant S-phase will cycle through to more sensitive phases, becoming more susceptible to cell death on the following treatment. Again, this is more likely to affect fast proliferating cells, resulting in an increased cell kill of the more rapidly dividing cells.</p>
<p>Re-population: Some cells survive mitosis between treatments and continue to multiply, making up for at least part of the radiation-induced cell loss. In this instance, the fast proliferating cells regain more cell population than the slowly proliferating cells, and the tissues they make up are more likely to survive. Since tumors generally consist of fast proliferating cells, the likelihood of tumor control is greatly decreased when the radiotherapy schedule is interrupted – and, thus, why such interruptions are strongly discouraged.</p>
<p>Re-oxygenation: Hypoxic tissues (those lacking oxygen) are more radio-resistant than<br />
well-oxygenated ones. Tumor cells often have multiple areas of poorly oxygenated tissue due to a poor vascular system, and longer diffusion distances, causing tumor necrosis.</p>
<p>Radiation (ionizing photons) interacts with water molecules to form highly reactive free radicals that are responsible for breaking strong chemical bonds, most importantly in DNA, leading to eventual cellular destruction. It appears that oxygen &#8220;fixes&#8221; or secures the radical damage on the DNA, making it unrepairable. Therefore, the damage is less likely to be ‘fixed’ if the environment lacks oxygen, rendering cells in hypoxic areas more resistant to radiation. As the surrounding cell population decreases following cell death, hypoxic areas will re-oxygenate between doses in a fractionated course of treatment. This re-oxygenation causes some initially resistant cells to become more sensitive to the next dose administration, which may improve tumor control by decreasing the radio-resistance caused by hypoxia. Since normal tissues are generally well oxygenated, re-oxygenation does not affect their cells.</p>
]]></content:encoded>
			<wfw:commentRss>http://dogparvosymptoms.org/radiation-therapy-time-dose-and-fractionation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

